EMA launches streamlined process to fast-track critical medicines, vaccines

The move is expected to be crucial during health crises

Hormone therapy for menopause gets green light from FDA

The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature

Kaiser Permanente’s study highlights power of genetics in preventing heart disease

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD

Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation

Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly

Eli Lilly to invest $1.2 billion in Puerto Rico to boost U.S. oral medicine production

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women

Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile

AstraZeneca's imfinzi cuts death risk by 22% in early gastric cancer

OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy